Identification

Summary

Calcium glubionate is a calcium salt indicated in the treatment of hypocalcemia, hyperkalemia, lead poisoning, and as an adjunct in the treatment of exudative skin conditions.

Generic Name
Calcium glubionate anhydrous
Commonly known or available as Calcium glubionate
DrugBank Accession Number
DB13142
Background

Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 592.513
Monoisotopic: 592.1163697
Chemical Formula
C18H32CaO19
Synonyms
  • (D-gluconato)(lactobionato)calcium
  • Calcium D-gluconate lactobionate
  • Calcium glubionate anhydrous
  • Glubionate calcium

Pharmacology

Indication

Calcium glubionate is indicated to treat conditions caused by low calcium levels such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany). It may also be used in certain patients to make sure they are getting enough calcium (e.g., women who are pregnant, nursing, or postmenopausal, people taking certain medications such as phenytoin, phenobarbital, or prednisone).

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Essential for nervous, muscular, and skeletal systems. Maintain cell membrane and capillary permeability. Act as an activator in the transmission of nerve impulses and contraction of cardiac, skeletal, and smooth muscle. Essential for bone formation and blood coagulation.

Absorption

Minimal unless chronic, high doses; absorption predominantly in the duodenum and dependent on calcitriol and vitamin D; mean absorption of calcium intake varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, adults 25%); during pregnancy, calcium absorption doubles; calcium is absorbed in soluble, ionized form; solubility of calcium is increased in an acid environment (IOM 2011); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia

Volume of distribution

Primarily in bones, teeth

Protein binding

~40%, primarily to albumin

Metabolism
Not Available
Route of elimination

Primarily feces (75%; as unabsorbed calcium); urine (22%)

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Assess patient for nausea, vomiting, anorexia, thirst, severe constipation, paralytic ileus, and bradycardia

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium glubionate anhydrous.
AcetyldigitoxinCalcium glubionate anhydrous may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium glubionate anhydrous.
AlfacalcidolThe risk or severity of adverse effects can be increased when Alfacalcidol is combined with Calcium glubionate anhydrous.
AmiodaroneThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium glubionate anhydrous.
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium glubionate anhydrous.
AtenololThe therapeutic efficacy of Atenolol can be decreased when used in combination with Calcium glubionate anhydrous.
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Calcium glubionate anhydrous which could result in a higher serum level.
BenzthiazideBenzthiazide may decrease the excretion rate of Calcium glubionate anhydrous which could result in a higher serum level.
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium glubionate anhydrous.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Calcium glubionate3CF7K0SD0Q12569-38-9OKRXSXDSNLJCRS-NLOQLBMISA-L
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
CALCIUM SANDOZ 10 ML 1,375 GR AMPUL, 5 ADETCalcium glubionate (1375 mg/10ml)InjectionIntramuscular; IntravenousNOVARTİS SAĞLIK GIDA VE TARIM ÜRÜNLERİ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag

Categories

ATC Codes
A12AA02 — Calcium glubionate
Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
93H20IU3DN
CAS number
97635-31-9
InChI Key
YPCRNBPOUVJVMU-LCGAVOCYSA-L
InChI
InChI=1S/C12H22O12.C6H12O7.Ca/c13-1-3(15)10(7(18)8(19)11(21)22)24-12-9(20)6(17)5(16)4(2-14)23-12;7-1-2(8)3(9)4(10)5(11)6(12)13;/h3-10,12-20H,1-2H2,(H,21,22);2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t3-,4-,5+,6+,7-,8-,9-,10-,12+;2-,3-,4+,5-;/m11./s1
IUPAC Name
{[(2R,3R,4R,5R)-2,3,5,6-tetrahydroxy-4-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexanoyl]oxy}calcio (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Ca]OC(=O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO

References

General References
  1. Drug Information [Link]
  2. TITCK Product Information: Calcium glubionate solution for injection [Link]
PubChem Compound
131704325
PubChem Substance
347829259
ChemSpider
58310
ChEMBL
CHEMBL2219740
Wikipedia
Calcium_glubionate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionIntramuscular; Intravenous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility47.2 mg/mLALOGPS
logP-2.5ALOGPS
logP-9.6ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)11.32ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area334.05 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity107.1 m3·mol-1ChemAxon
Polarizability50.17 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at November 04, 2016 20:50 / Updated at June 12, 2021 10:55